Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106676011) on January 06, 2026, and is solely responsible for the information contained therein.